Efficacy measure | All patients (n = 50) |
---|---|
Objective response, n (%) | 36 (72) |
   Complete response | 2 (4) |
   Partial response | 34 (68) |
Stable disease, n (%) | 10 (20) |
Progressive disease, n (%) | 4 (8) |
Mean overall survival, months (95% CI) | 38.0 (32.65 to 43.35) |
Median recurrence-free survival, responders; mts (95% CI) | 24.73 (4.50 to 44.97) |